ImmuCell Corp Margin Rises to 41% as Net Loss Narrows to $1M
ImmuCell Corp cut its net loss to $1 million in 2025 while raising gross margin to 41% from 30% with higher volumes. Q4 expenses climbed to $3 million and international sales plunged over 50%, yet production capacity can scale to 5–6 million units annually without major outlays.
1. Financial Results for 2025
ImmuCell Corp reported a net loss of $1 million for 2025, an improvement from the prior year. Gross margin rose to 41% from 30% driven by increased manufacturing volumes and operational efficiencies, while Q4 revenues fell 1.6% due to backorder catch-up dynamics and operating expenses increased to $3 million from $2.2 million a year earlier.
2. International Sales and Market Share
International sales in Q4 2025 declined by more than 50% year-over-year, primarily reflecting order timing in Canada. Despite this drop, ImmuCell maintained a 15% share of treated calves in the US and captured approximately 29% of spending in the calf scours prevention category, underscoring its market leadership.
3. Capacity Expansion and Strategic Focus
The company identified opportunities to boost annual production capacity to 5–6 million units without significant capital investments through floor plan optimization and equipment maintenance. ImmuCell plans to focus resources on its First Defense scours prevention product line while pausing investment in subclinical mastitis offerings to drive top-line growth.